However, in melanoma cells presenting the NRAS mutation, vemurafenib is thought to inhibit only one RAF promoter in the dimer, whereas the other one remains active and maintains signals for downstream activation of MAPK/ERK pathway. The gene discussed is MAPK1; the disease is melanoma.